Oslif Breezhaler (Indacaterol)

Indacaterol is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in chronic respiratory disease.

• Chronic obstructive pulmonary disease (COPD): provides once‑daily maintenance bronchodilation and reduces exacerbation risk.
• Exercise‑induced bronchoconstriction: improves tolerance to physical activity in patients with underlying airway hyper‑responsiveness.
• Asthma (as add‑on therapy): offers additional bronchodilation when standard inhaled corticosteroids and long‑acting agents are insufficient.

• Indacaterol selectively stimulates β2‑adrenergic receptors on airway smooth‑muscle cells, increasing cyclic AMP levels and causing relaxation of the bronchial smooth muscle. This results in prolonged bronchodilation, improving airflow and reducing airway resistance in the lungs.

Indacaterol may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Cough
• Throat irritation
• Nasal congestion
• Headache
• Dry mouth
• Upper respiratory tract infection

Serious or Rare Side Effects

• Paradoxical bronchospasm
• Cardiovascular events such as tachycardia or palpitations
• Severe hypersensitivity reactions including anaphylaxis
• Pneumonia
• Significant drop in blood pressure
• Acute worsening of COPD symptoms

When using Oslif Breezhaler, patients and healthcare providers should consider several safety measures.

• Assess respiratory status: evaluate baseline lung function before initiating therapy.
• Monitor cardiovascular health: watch for tachycardia, arrhythmias, or hypertension.
• Review concomitant medications: avoid duplicate β2‑agonist therapy.
• Caution in severe COPD: patients with very low FEV1 may require additional monitoring.
• Educate on proper inhaler technique: ensure correct device handling to achieve intended dose.
• Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Indacaterol can interact with other medicines that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid)

• Non‑selective β‑blockers: may blunt bronchodilator response and precipitate bronchospasm.
• Monoamine oxidase inhibitors (MAOIs): increase risk of tachycardia and hypertensive episodes.

Moderate Interactions (Monitor Closely)

• Other long‑acting β2‑agonists or short‑acting bronchodilators: may increase risk of cardiovascular side effects.
• Diuretics: potential additive effect on heart rate and blood pressure.
• Theophylline: may enhance β2‑agonist effects, requiring careful observation.